FLT3 and acute myeloid leukemia: Future research is investigating new ways to overcome the reduced sensitivity to venetoclax of AML cells with novel combination therapies such as MCL-1, FLT3, MEK1/2 and mitochondrial complex inhibitors, which need to be evaluated in a clinical setting.